AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28710563 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical group
Number of subjects: 33
Study 28710747 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-HER2 cells infused after conditioning treatment with nab-paclitaxel (100-200 mg/m2)
Number of subjects: 0
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay for SMN1 deletion
Number of subjects: 120267
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS ddPCR screening assay
Number of subjects: 120267
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of SMA
Number of subjects: 120267
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of SMA
Number of subjects: 120267
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn screening
Number of subjects: 120267
Study 28711173 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RT-PCR and ddPCR
Number of subjects: 120267
Study 28711743 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPLe 1.0 smartphone application
Number of subjects: 51
Study 28711743 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPLe 1.0 smartphone application (completers)
Number of subjects: 51
Study 28711743 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPLe 1.0 smartphone application (after ANCOVA)
Number of subjects: 51
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of first-line bevacizumab
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor (EGFR)-directed therapies
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomarkers (BRAF, HER2, mismatch repair deficiency)
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination strategies
Number of subjects: 0
Study 28712102 — intervention group
Group type: EXPERIMENTAL
Intervention: New biologic therapies with novel targets
Number of subjects: 0
Study 28712360 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum infections in HIV-uninfected Mozambican women
Number of subjects: 1714
Study 28712360 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum infections in HIV-uninfected Gabonese women
Number of subjects: 1714
Study 28712360 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum infections in HIV-uninfected Beninese women
Number of subjects: 1714
Study 28712360 — intervention group
Group type: EXPERIMENTAL
Intervention: Past or chronic placental P. falciparum infection in Mozambican newborns
Number of subjects: 1714
Study 28712360 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling qPCR-peripheral parasite densities in Mozambican women
Number of subjects: 1714
Study 28712360 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected women from Kenya
Number of subjects: 1714
Study 28712360 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected women from Mozambique
Number of subjects: 1714
Study 28712533 — intervention group
Group type: EXPERIMENTAL
Intervention: 60Gy intensity modulated radiotherapy with concurrent weekly intravenous cisplatinum
Number of subjects: 43
Study 28712602 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate (7.5mEq/kg per day)
Number of subjects: 3
Study 28712602 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (400mg/kg per day)
Number of subjects: 3
Study 28712602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine α-ketoglutarate (400mg/kg per day)
Number of subjects: 3
Study 28712815 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid stenosis patients
Number of subjects: 144
Study 28712815 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid stenosis patients with reduced BHI
Number of subjects: 144
Study 28712815 — intervention group
Group type: COMPARATOR
Intervention: Control patients without stenosis
Number of subjects: 144
Study 28713060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic imaging using a standardized protocol (high-definition white light and narrow-band imaging)
Number of subjects: 83
Study 28713060 — intervention group
Group type: COMPARATOR
Intervention: Endoscopically designated non-dysplastic SSPs
Number of subjects: 83
Study 28713062 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation colon capsule endoscopy (CCE-2)
Number of subjects: 150
Study 28713063 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of the gastric remnant pouch
Number of subjects: 25
Study 28713063 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 28713256 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 0
Study 28713256 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 28713365 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection and quantification of immune compounds in human milk
Number of subjects: 0
Study 28713581 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated protein intake (EPI, 20% of daily calorie intake)
Number of subjects: 12
Study 28713581 — intervention group
Group type: COMPARATOR
Intervention: Recommended protein intake (RPI, 10% of daily calorie intake)
Number of subjects: 12
Study 28713801 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer workshop (TTT)
Number of subjects: 56
Study 28714866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 32
Study 28714866 — intervention group
Group type: COMPARATOR
Intervention: Acalabrutinib
Number of subjects: 32
Study 28714866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 32
Study 28714868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR)
Number of subjects: 16
Study 28716015 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status assessment through medical examination, past medical history, haemoglobin concentration, HIV and malaria testing.
Number of subjects: 421
Study 28716018 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analysis of cardiorespiratory signals prior to planned extubation.
Number of subjects: 250
Study 28716049 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 criteria for AUD
Number of subjects: 304
Study 28716049 — intervention group
Group type: COMPARATOR
Intervention: DSM-IV criteria for AUD
Number of subjects: 304
Study 28716049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DSM-IV and DSM-5 criteria for AUD
Number of subjects: 304
Study 28716049 — intervention group
Group type: COMPARATOR
Intervention: Neither DSM-5 nor DSM-IV criteria for AUD
Number of subjects: 304
Study 28716049 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 alone
Number of subjects: 304
Study 28716065 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 survey for physical component scores
Number of subjects: 0
Study 28716065 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 survey for mental component scores
Number of subjects: 0
Study 28716065 — intervention group
Group type: EXPERIMENTAL
Intervention: HSUV measurements
Number of subjects: 0
Study 28716065 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC analysis
Number of subjects: 0
Study 28716114 — intervention group
Group type: EXPERIMENTAL
Intervention: Visumax femtosecond laser (FSL)
Number of subjects: 60
Study 28716114 — intervention group
Group type: COMPARATOR
Intervention: Moria M2 microkeratome (MK)
Number of subjects: 60
Study 28716404 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisionless magnetic anastomosis system (IMAS) for partial jejunal diversion (PJD)
Number of subjects: 10
Study 28716771 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention (Stick To It) including online enrollment, web-based activities (quizzes, reminders), and in-person activities at sexual health clinics.
Number of subjects: 60
Study 28716771 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention (Stick To It)
Number of subjects: 60
Study 28716771 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (individuals meeting inclusion criteria who attended study clinics in the 12 months prior to intervention implementation)
Number of subjects: 60
Study 28716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital notification application used by ambulance clinicians
Number of subjects: 0
Study 28716801 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone blockade
Number of subjects: 130
Study 28716801 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACR-ve diabetes mellitus patients and healthy controls)
Number of subjects: 130
Study 28716801 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR+ve diabetes mellitus patients after 1-year treatment with renin-angiotensin-aldosterone blockade
Number of subjects: 130
Study 28716862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous gene therapy using a self-inactivating lentiviral vector (LV-w1.6 WASp) after reduced-intensity conditioning
Number of subjects: 1
Study 28716981 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up noncontrast CT imaging
Number of subjects: 242
Study 28716981 — intervention group
Group type: COMPARATOR
Intervention: Baseline variables alone
Number of subjects: 242
Study 28716981 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor recanalization on CTA
Number of subjects: 242
Study 28716981 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor reperfusion on CTP
Number of subjects: 242
Study 28716981 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable outcome defined as modified Rankin Scale 3 to 6
Number of subjects: 242
Study 28716989 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite FMD (string-of-beds or focal stenoses affecting at least 2 vascular beds)
Number of subjects: 469
Study 28716989 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site disease with dissections or aneurisms
Number of subjects: 469
Study 28716989 — intervention group
Group type: COMPARATOR
Intervention: Cerebrovascular presentation with hypertension
Number of subjects: 469
Study 28716989 — intervention group
Group type: COMPARATOR
Intervention: Renal presentation with bilateral RA lesions
Number of subjects: 469
Study 28717036 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care workers (HCWs) wearing gowns and gloves (G&G) during usual care activities.
Number of subjects: 185
Study 28717036 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of care provided by HCWs.
Number of subjects: 185
Study 28717404 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min per week of aerobic physical activity
Number of subjects: 400
Study 28717404 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min per week of aerobic physical activity
Number of subjects: 400
Study 28717512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for PTSD (DBT-PTSD)
Number of subjects: 23
Study 28717516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Darbepoetin (DA)
Number of subjects: 50
Study 28717516 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Epoetin (EPO)
Number of subjects: 50
Study 28718100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB) exposure for 142 min
Number of subjects: 2280
Study 28718100 — intervention group
Group type: COMPARATOR
Intervention: No CPB exposure
Number of subjects: 2280
Study 28718760 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and plerixafor
Number of subjects: 0
Study 28719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + peginterferon alfa 2a + ribavirin (SOF+PR) for 12 weeks
Number of subjects: 50
Study 28719029 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin (SOF+R) for 24 weeks
Number of subjects: 50
Study 28719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural social support (living with others, having a caregiver)
Number of subjects: 282
Study 28719225 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional social support (measured with the Medical Outcomes Social Support Survey)
Number of subjects: 282
Study 28719496 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 200
Study 28719502 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 387
Study 28719652 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVconsv vaccine (plasmid DNA, simian adenovirus, poxvirus MVA)
Number of subjects: 12
Study 28719652 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVconsv vaccine
Number of subjects: 12
Study 28720095 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating fibrocytes measurement using a modified faster method without intracellular staining.
Number of subjects: 0
Study 28720095 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional culture method for measuring mature fibrocytes in vitro.
Number of subjects: 0
Study 28720095 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28720129 — intervention group
Group type: EXPERIMENTAL
Intervention: RTW-focused approach in therapy
Number of subjects: 164
Study 28720129 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline work ability and expectancy of future work ability, history of psychiatric treatment, focus on RTW in treatment
Number of subjects: 164
Study 28720129 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in expectations of future work ability at post-treatment
Number of subjects: 164
Study 28720370 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28720549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vectors injected into the resection cavity or remaining tumor (one expressing HSV-1 thymidine kinase and the other expressing Flt3L).
Number of subjects: 0
Study 28720549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vector expressing Flt3L.
Number of subjects: 0
Study 28720549 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1/ganciclovir treatment.
Number of subjects: 0
Study 28720557 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized text messaging
Number of subjects: 225
Study 28720557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 225
Study 28720557 — intervention group
Group type: COMPARATOR
Intervention: Website-control
Number of subjects: 225
Study 28721051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 26
Study 28721067 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg pasireotide long-acting release (LAR) i.m.
Number of subjects: 29
Study 28721067 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg pasireotide long-acting release (LAR) i.m.
Number of subjects: 29
Study 28721080 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic therapy
Number of subjects: 84
Study 28721080 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 84
Study 28721449 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T cells (Tregs)
Number of subjects: 0
Study 28723307 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of longitudinal patient-reported outcomes (PROs)
Number of subjects: 21758
Study 28723307 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCTs)
Number of subjects: 21758
Study 28724134 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1273
Study 28724134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1273
Study 28724134 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1273
Study 28724373 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Groups (FG) and Key Informant Interviews (KI) with hospital staff
Number of subjects: 133
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to and use of cell phones in the bedroom during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to and use of computers in the bedroom during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to and use of TVs in the bedroom during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cell phones during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of computers during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to and use of TVs, cell phones, tablets, and video games in the bedroom
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to and use of a TV and computer during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rarely reading a printed book in the bedroom during the hour before sleep
Number of subjects: 2334
Study 28724380 — intervention group
Group type: EXPERIMENTAL
Intervention: Having access to an EECD in the bedroom
Number of subjects: 2334
Study 28724380 — intervention group
Group type: COMPARATOR
Intervention: Frequent reading of a printed book in the bedroom during the hour before sleep
Number of subjects: 2334
Study 28724434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernese Pain Scale for Neonates (BPSN) assessment during heel sticks
Number of subjects: 100
Study 28724434 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual contextual factors (gestational age, gender, number of painful procedures)
Number of subjects: 100
Study 28724445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined plasmapheresis (PE) and allogeneic mesenchymal stem cells transplantation (MSCT) therapy
Number of subjects: 14
Study 28724513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, Web-based HIV prevention intervention (6-session program)
Number of subjects: 180
Study 28724513 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition (HIV/STI information from sex education websites)
Number of subjects: 180
Study 28724646 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylamine treatment, dosage and duration not specified
Number of subjects: 0
Study 28724646 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28724795 — intervention group
Group type: COMPARATOR
Intervention: LXA4 and 15-epi-LXA4 levels in bronchoalveolar lavage (BAL) fluid
Number of subjects: 69
Study 28724795 — intervention group
Group type: COMPARATOR
Intervention: SAA levels in BAL fluid
Number of subjects: 69
Study 28724795 — intervention group
Group type: COMPARATOR
Intervention: ALX receptor expression in BAL macrophages
Number of subjects: 69
Study 28724795 — intervention group
Group type: COMPARATOR
Intervention: LXA4loSAAhi levels
Number of subjects: 69
Study 28724795 — intervention group
Group type: COMPARATOR
Intervention: SAA and aliquots of LXA4loSAAhi BAL fluid
Number of subjects: 69
Study 28725257 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding relaxation therapy (daily audio recording during breastfeeding)
Number of subjects: 0
Study 28725257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 0
Study 28725451 — intervention group
Group type: EXPERIMENTAL
Intervention: WheelSeeU (peer-led wheelchair training program)
Number of subjects: 40
Study 28725451 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 28725452 — intervention group
Group type: EXPERIMENTAL
Intervention: MapMySmoke app
Number of subjects: 8
Study 28725594 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly infusions of ascorbic acid (AA); week 1: 5 g, week 2: 30 g, weeks 3-12: 60 g
Number of subjects: 23
Study 28725594 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly infusions of ascorbic acid (AA)
Number of subjects: 23
Study 28726115 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe CCA in non-dialysis patients (Ca group)
Number of subjects: 1546
Study 28726115 — intervention group
Group type: COMPARATOR
Intervention: None-to-mild CCA in non-dialysis patients (non-Ca group)
Number of subjects: 1546
Study 28726115 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe CCA in dialysis patients (Ca group)
Number of subjects: 1546
Study 28726115 — intervention group
Group type: COMPARATOR
Intervention: None-to-mild CCA in dialysis patients (non-Ca group)
Number of subjects: 1546
Study 28727542 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided high-intensity focused ultrasound (HIFU) ablation
Number of subjects: 30
Study 28727583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine and bupivacaine HCl mixture (266 mg liposomal bupivacaine and 125 mg 0.25% bupivacaine HCl with epinephrine 1:300,000)
Number of subjects: 40
Study 28728650 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Onyx 2.0-mm zotarolimus-eluting stent
Number of subjects: 101
Study 28728652 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-reported FFR measurements
Number of subjects: 763
Study 28728652 — intervention group
Group type: COMPARATOR
Intervention: CL-analyzed FFR measurements
Number of subjects: 763
Study 28728652 — intervention group
Group type: COMPARATOR
Intervention: Tracings with signal drift
Number of subjects: 763
Study 28728652 — intervention group
Group type: COMPARATOR
Intervention: Tracings with waveform artifacts
Number of subjects: 763
Study 28728652 — intervention group
Group type: COMPARATOR
Intervention: Predictors of distorted waveforms
Number of subjects: 763
Study 28728686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-associated spontaneous coronary artery dissection (P-SCAD)
Number of subjects: 323
Study 28728751 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib 800mg orally every day (1 cycle = 28 days) until disease progression or prohibitive toxicity
Number of subjects: 28